Form D · Biotechnology
Xenagos Bio, Inc.
Philadelphia, PA · CIK 0002134608
Offering snapshot reported May 15, 2026 · SEC filing
- Reported sold
- $2.52M Offering amount: $2.52M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2026 | Initial | $2,520,000 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-584166
Source: Form D, filed May 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abel De La Rosa | Director |
| Patrick Higgins | Director |
| Michael J. Mc Elhaugh | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
121 S. Broad St., 15 Th Floor, #1015
Philadelphia, PA, 19107
Philadelphia, PA, 19107